Pacira Biosciences Inc PCRX:NASDAQ

Last Price$43.82NASDAQ Previous Close - Last Trade as of 3:59PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$43.82 (50)
Ask (Size)$43.84 (1)
Day Low / HighN/A - N/A
Volume626.5 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 01/17/2020

 

Pacira Biosciences Inc ( NASDAQ )

Price: $43.82
Change: -0.18 (0.41%)
Volume: 626.5 K
3:59PM ET 1/17/2020
 
 

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $12.60
Change: -0.11 (0.87%)
Volume: 1.4 M
4:00PM ET 1/17/2020
 
 

Prestige Consumer Healthcare Inc ( NYSE )

Price: $42.20
Change: +0.31 (0.74%)
Volume: 260.8 K
6:30PM ET 1/17/2020
 
 

Corcept Therapeutics Inc ( NASDAQ )

Price: $12.90
Change: -0.24 (1.83%)
Volume: 516.7 K
4:00PM ET 1/17/2020
 
 

Innoviva Inc ( NASDAQ )

Price: $14.43
Change: -0.08 (0.55%)
Volume: 394.8 K
4:00PM ET 1/17/2020
 

Read more news Recent News

Pacira Pre-Announces Q4 Revenue Above Street View
8:37AM ET 1/09/2020 MT Newswires

Pacira BioSciences (PCRX), a provider of innovative non-opioid pain management options, reported pre-market Thursday preliminary Q4 revenue of $122.4...

Earnings Forecast for Pacira Biosciences in 2020 Targeted Higher
12:45AM ET 1/09/2020 MT Newswires

2020`s forecasted earnings estimate for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 43.10) for the year ending December 31, 2020 has been increased....

2020 Earnings Estimate for Pacira Biosciences Reduced
1:10AM ET 1/08/2020 MT Newswires

The 2020 forecasted earnings estimate for Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 42.59) for the year ending December 31, 2020 has been...

Pacira Pharmaceuticals Reports Positive Results from Study of Exparel in Cesarean Section Patients
8:54AM ET 1/07/2020 MT Newswires

Pacira Pharmaceuticals (PCRX) reported that its phase 4 study of Exparel, an injectable drug for patients undergoing a Cesarean section, achieved its...

Company Profile

Business DescriptionPacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
Address5 Sylvan Way
Parsippany, New Jersey 07054
Phone+1.973.254.3560
Number of Employees518
Recent SEC Filing01/17/20204
Chairman, Chief Executive & Operating OfficerDavid M. Stack
PresidentMax Reinhardt
Chief Financial OfficerCharles A. Reinhart
Vice President-Research & DevelopmentVladimir Kharitonov

Company Highlights

Price Open$44.09
Previous Close$44.00
52 Week Range$34.64 - 49.50
Market Capitalization$1.8 B
Shares Outstanding41.7 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement02/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings1.1K
Earnings per Share$0.32
Beta vs. S&P 500N/A
Revenue$337.3 M
Net Profit Margin0.55%
Return on Equity0.65%

Analyst Ratings as of 11/04/2019

Buy
9
Overweight
0
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset